-
公开(公告)号：US20230166034A1
公开(公告)日：2023-06-01
申请号：US17752236
申请日：2022-05-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Ashutosh ZADE
CPC classification number: A61M5/1723 , A61M5/14244 , G16H20/17 , A61M2230/201 , A61M2005/14208
Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.
-
公开(公告)号：US20220379028A1
公开(公告)日：2022-12-01
申请号：US17818504
申请日：2022-08-09
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR
Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
-
公开(公告)号：US20220293234A1
公开(公告)日：2022-09-15
申请号：US17691829
申请日：2022-03-10
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG
Abstract: The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and/or persistence of glucose excursions relative to a target glucose level.
-
24.发明申请公开(公告)号：US20220288300A1
公开(公告)日：2022-09-15
申请号：US17330115
申请日：2021-05-25
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Trang LY
Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
-
公开(公告)号：US20220287633A1
公开(公告)日：2022-09-15
申请号：US17685937
申请日：2022-03-03
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Ashutosh ZADE , Joon Bok LEE
Abstract: Disclosed are processes and techniques implementable by devices and a drug delivery system to maintain optimal drug delivery for a user according to a user's diabetes treatment plan. The disclosed techniques enable a drug delivery device that received an analyte measurement value from an analyte sensor during a prior cycle time to determine a present analyte measurement value has not been received during a present cycle time. A processor of the drug delivery device may, in response to the determination, initiate an action to obtain the present analyte measure value from another device or an estimate of the present analyte measurement value. Based on an outcome of the initiated action, the processor may calculate a dosage of the drug using the present analyte measurement value or information related to the present analyte measurement value. The drug delivery device may also be operable to output the calculated dosage of the drug.
-
Patent Agency Ranking
公开(公告)号：US20220241503A1
公开(公告)日：2022-08-04
申请号：US17578716
申请日：2022-01-19
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Joon Bok LEE
Abstract: The disclosed examples provide techniques and devices for determining a daily basal profile or an adjusted basal need for a drug based on a collection of data that is filtered and processed. A controller may be configured to evaluate a history of drug delivery in both basal and bolus dosages and generate a daily basal profile or an adjusted basal need that is a time dependent that may be used to schedule basal dosages of a drug that more closely addresses a user's drug needs over the course of a time period, such as a day, week or the like.
-
公开(公告)号：US20220203023A1
公开(公告)日：2022-06-30
申请号：US17514336
申请日：2021-10-29
Applicant: Insulet Corporation
Inventor： Jason O'CONNOR , Joon Bok LEE , David NAZZARO , Yibin ZHENG , Pauline TANDON
Abstract: A system for automatically delivering medication to a user is disclosed. A sensor worn by the user can collect information regarding the user. A user device, for example, a smartphone, executes a user application that uses the collected information to determine an amount of medication to provide to the user. The user application includes a graphical user interface that allows the user to easily interact with the user application to specify various aspects of the delivery of the medication. The user application controls a wearable drug delivery device to dispense the medication to the user.
-
公开(公告)号：US20220062548A1
公开(公告)日：2022-03-03
申请号：US17406209
申请日：2021-08-19
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Rangarajan NARAYANASWAMI , Joon Bok LEE
Abstract: Disclosed are systems, devices, methods and computer-readable medium products that compensate for consumption of a meal by providing a reduced-constraint meal bolus dosage. The reduced-constraint meal bolus dosage is determined using post-prandial safety constraints that are reduced based on an indication that a meal has been consumed. The post-prandial safety constraints are intended to protect users from overdelivering or underdelivering insulin to the user. The determinations may be performed by a control algorithm-based drug delivery system that enables automatic delivery of a drug, such as insulin or the like.
-
公开(公告)号：US20220062546A1
公开(公告)日：2022-03-03
申请号：US17008101
申请日：2020-08-31
Applicant: Insulet Corporation
Inventor： Eric BENJAMIN , Jason O'CONNOR , Yibin ZHENG , Joon Bok LEE , Mark BOYNS
IPC: A61M5/172 , G16H50/30 , G16H40/40 , G16H40/67 , G16H50/20 , G16H50/70 , G16H10/60 , G16H20/13 , G06F9/445
Abstract: The exemplary embodiments allow a user to have more aggressive settings or less aggressive settings for an AID system after demonstrating good blood glucose level control. This allows the settings to be more quickly customized to users that demonstrate good quality blood glucose level control than conventional systems. As these users have demonstrated good quality glucose level control there is less of a need to constrain the settings and provide a high margin of safety. Conversely, users demonstrating poor quality blood glucose level control may have less aggressive settings imposed, representing a higher margin of safety.
-
30.发明申请公开(公告)号：US20210244880A1
公开(公告)日：2021-08-12
申请号：US16788892
申请日：2020-02-12
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR , Trang LY , Yibin ZHENG , Connor GULLIFER , Kyle GROVER
Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.
-
-
-
-
-
-
-
-
-
Search Results
96
records
(took 0.018 seconds)
